Gut-Brain Axis in Autism Spectrum Disorder: A Bibliometric and Microbial-Metabolite-Neural Pathway Analysis
Open Journal of Neuroscience · 2025
DOI: 10.31586/ojn.2025.6169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Journal of Neuroscience, 2025. Verfasst von Avam Arora.
Abstract (Originalsprache)
The gut-brain axis (GBA) has emerged as a central focus in the study of neurodevelopmental disorders, particularly autism spectrum disorder (ASD). Research suggests that microbial composition and its metabolic byproducts influence neural development, synaptic plasticity, and behavior [1,2,3]. A structured bibliometric analysis of Scopus and Web of Science records was performed using Bibliometrix and VOSviewer to trace trends and thematic evolution of GBA–ASD literature [7,8]. In parallel, a data-driven pathway modeling approach maps microbial metabolites (e.g., short-chain fatty acids, tryptophan catabolites) to host signaling pathways including vagal stimulation, immune cytokine modulation, and blood–brain barrier (BBB) permeability [4,5]. Simulations implemented in Python’s NetworkX illustrate how perturbations in metabolite flux may influence CNS outcomes. The findings reveal growing emphasis on butyrate, serotonin, microglial priming, and maternal immune activation in ASD-related GBA studies, and highlight the need for rigorous empirical validation of computational predictions [9,10,11].
Zitieren
APA
Arora, A. (2025). Gut-Brain Axis in Autism Spectrum Disorder: A Bibliometric and Microbial-Metabolite-Neural Pathway Analysis. Open Journal of Neuroscience. https://doi.org/10.31586/ojn.2025.6169
Vancouver
Arora A. Gut-Brain Axis in Autism Spectrum Disorder: A Bibliometric and Microbial-Metabolite-Neural Pathway Analysis. Open Journal of Neuroscience. 2025. doi:10.31586/ojn.2025.6169
BibTeX
@article{Arora2025,
author = {Arora, Avam},
title = {Gut-Brain Axis in Autism Spectrum Disorder: A Bibliometric and Microbial-Metabolite-Neural Pathway Analysis},
journal = {Open Journal of Neuroscience},
year = {2025},
doi = {10.31586/ojn.2025.6169}
}
EUVIMED